l e t t e r s Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases (RGNs) are highly efficient genome editing tools 1-3 . CRISPR-associated 9 (Cas9) RGNs are directed to genomic loci by guide RNAs (gRNAs) containing 20 nucleotides that are complementary to a target DNA sequence. However, RGNs can induce mutations at sites that differ by as many as five nucleotides from the intended target 4-6 . Here we report that truncated gRNAs, with shorter regions of target complementarity <20 nucleotides in length, can decrease undesired mutagenesis at some off-target sites by 5,000-fold or more without sacrificing on-target genome editing efficiencies. In addition, use of truncated gRNAs can further reduce off-target effects induced by pairs of Cas9 variants that nick DNA (paired nickases). Our results delineate a simple, effective strategy to improve the specificities of Cas9 nucleases or paired nickases.
l e t t e r s Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases (RGNs) are highly efficient genome editing tools [1] [2] [3] . CRISPR-associated 9 (Cas9) RGNs are directed to genomic loci by guide RNAs (gRNAs) containing 20 nucleotides that are complementary to a target DNA sequence. However, RGNs can induce mutations at sites that differ by as many as five nucleotides from the intended target [4] [5] [6] . Here we report that truncated gRNAs, with shorter regions of target complementarity <20 nucleotides in length, can decrease undesired mutagenesis at some off-target sites by 5,000-fold or more without sacrificing on-target genome editing efficiencies. In addition, use of truncated gRNAs can further reduce off-target effects induced by pairs of Cas9 variants that nick DNA (paired nickases). Our results delineate a simple, effective strategy to improve the specificities of Cas9 nucleases or paired nickases.
The Streptococcus pyogenes Cas9 nuclease (hereafter referred to as Cas9) can robustly induce insertion or deletion mutations (indels) or precise alterations through repair of Cas9-induced double-stranded breaks by nonhomologous end-joining (NHEJ) or homology-directed repair (HDR), respectively. However, unwanted indel mutations can also be induced at off-target sites that share sequence similarity with the on-target site [4] [5] [6] . Recently, several approaches to improve the specificity of RNA-guided Cas9 have been described, including truncation of the 3′ end of gRNA (which is derived from the transactivating CRISPR RNA or 'tracrRNA' domain that is believed to mediate interaction with Cas9) or addition of two guanine nucleotides to the 5′ end of the gRNA (just before the 20-nt complementarity region); however, RGNs using these altered gRNAs can have decreased on-target activities 6, 7 . Alternatively, a 'paired nicking' strategy (originally implemented with pairs of closely spaced zinc finger nickases 8 ), in which two gRNAs targeted to adjacent sites on opposite DNA strands each recruit a Cas9 variant (Cas9-D10A) that nicks DNA instead of cutting both strands 7, 9, 10 , can reduce mutation frequencies at known off-target sites of single gRNA-guided Cas9 nuclease in human cells 7, 10 . Nevertheless, indel mutations can still be observed at some off-target sites 10 , and the addition of a second gRNA might introduce new off-target mutations because a single gRNA-directed Cas9 nickase can efficiently induce indels at some sites 7, 9, 11 . In addition, the need to express appropriately positioned and oriented paired gRNAs presents technical challenges if implemented with multiplex [12] [13] [14] or genome-wide, library-based applications of RGNs 15, 16 . Finally, the paired nickase strategy cannot be used to improve the specificities of catalytically inactive Cas9 (dCas9) fused to heterologous effectors, such as transcriptional activation domains [17] [18] [19] . Thus, the development of additional methods to improve the specificity of Cas9-based systems remains an important priority.
We hypothesized that off-target effects of RGNs might be minimized by decreasing the length of the gRNA-DNA interface. Such an approach might seem counterintuitive, but we 20 and others 7,10 have shown that lengthening the 5′ end of the complementary region can reduce on-target editing efficiency, with some of these longer gRNAs processed back to standard length in human cells 10 . In contrast, certain gRNAs bearing either truncations or progressively greater numbers of mismatches at the 5′ end of their targeting complementarity regions have been shown to retain robust Cas9-mediated, on-target cleavage activities 4, 9, 21 . We hypothesized that these 5′-end nucleotides might not be necessary for full gRNA activity and that these nucleotides might normally compensate for mismatches at other positions along the gRNA-target DNA interface; therefore, we reasoned that shorter gRNAs might be more sensitive to mismatches and thus more specific (Supplementary Fig. 1) .
To test our predictions, we constructed a series of progressively shorter gRNAs for a target site in the EGFP reporter gene containing 15, 17, 19 or 20 complementary nucleotides (Online Methods and Fig. 1a ). We measured the abilities of these gRNAs to direct Cas9induced indels at this target site in human U2OS.EGFP cells by quantifying mutation of a single integrated and constitutively expressed EGFP gene 4, 22 . gRNAs that have 17 or 19 nucleotides of target complementarity showed activities comparable to the full-length gRNA with 20 nucleotides of complementarity, whereas a gRNA containing 15 nucleotides of complementarity failed to show activity ( Fig. 1b) .
To extend the generality of these findings, we assayed full-length gRNAs and matched gRNAs with 18, 17 and/or 16 nucleotides that are complementary to four additional EGFP reporter gene sites (EGFP sites 1, 2, 3 and 4; Fig. 1c ). For all four target sites, gRNAs with 17 or 18 nucleotides of complementarity functioned as efficiently as (or, in one case, more efficiently than) their matched full-length l e t t e r s counterparts ( Fig. 1c) . gRNAs with only 16 nucleotides of complementarity showed substantially decreased or undetectable activities at the two sites for which they could be made ( Fig. 1c) . Given these results, in this report we refer to truncated gRNAs with complementarity lengths of 17 or 18 nucleotides as "tru-gRNAs" and RGNs using these tru-gRNAs as "tru-RGNs."
To determine whether tru-RGNs could efficiently edit endogenous genes, we constructed tru-gRNAs for seven sites in three human genes (VEGFA, EMX1 and CLTA), including four sites targeted in previous studies [4] [5] [6] 10 (Fig. 1d) . Five of these seven tru-gRNAs induced Cas9-mediated indel mutations with efficiencies comparable to those mediated by matched standard-length RGNs (Fig. 1d) , with the two tru-gRNAs that had lower activities than their full-length counterparts still exhibiting high absolute rates of mutagenesis (means of 13.3% and 16.6%) ( Fig. 1d) . Sanger sequencing confirmed that indels introduced by tru-RGNs originate at the expected site of cleavage and are essentially indistinguishable from those induced by their standard counterpart RGNs (Supplementary Fig. 2 ). We also found that tru-gRNAs containing a mismatched 5′ G and 17 nucleotides of complementarity could efficiently direct Cas9-induced indels, whereas those bearing a mismatched 5′ G and 16 nucleotides of complementarity showed lower or undetectable activities compared with matched fulllength gRNAs (Supplementary Fig. 3 l e t t e r s single-stranded oligodeoxynucleotides (ssODNs) and found that they did so for two sites in the VEGFA and EMX1 genes with efficiencies comparable to or higher than those of matched, standard RGNs ( Fig. 1e) . We conclude that tru-RGNs can function efficiently to introduce on-target indels or HDR-mediated genome editing events in human cells.
To assess the specificities of tru-RGNs, we first tested whether they possess greater sensitivity to Watson-Crick mismatches at the gRNA-DNA interface by testing variants of the full-length and tru-gRNAs we had previously made for EGFP sites #1, #2 and #3 (Fig. 1c) . These variant gRNAs contain single substitutions or adjacent double substitutions at each position within the complementarity region (except the 5′ G) ( Fig. 2a,b ). Using the EGFP disruption assay in human U2OS. EGFP cells, we found that tru-RGNs were generally more sensitive to single and adjacent double mismatches than standard RGNs (compare bottom and top panels of Fig. 2a,b ). Magnitudes of sensitivity to mismatches were site-dependent, with tru-RGNs to EGFP site #1 exhibiting less sensitivity to single and double mismatches than tru-RGNs to EGFP site #2 and #3. Note that EGFP site #1 tru-gRNAs have 18 complementary nucleotides whereas the others have 17.
We next examined whether tru-RGNs have reduced genomic offtarget effects in human cells by using matched full-length and tru-gRNAs targeted to VEGFA site 1, VEGFA site 3 and EMX1 site 1 (Fig. 1d) . We chose these target sites because previous studies had defined a total of 13 off-target sites for the full-length gRNAs targeted to these sequences 4, 5 . tru-RGNs exhibited substantially reduced mutagenesis activities relative to matched standard RGNs at all 13 previously identified off-target sites in human U2OS.EGFP cells ( Table 1) , with 11 sites having mutation frequencies below the reliable detection limit (2-5%) of the T7 endonuclease I (T7EI) assay (Online Methods) used for these experiments ( Table 1) . We also observed similar results in a different human cell line (FT-HEK293 cells) ( Supplementary Table 1 ).
To allow more sensitive detection of off-target mutations, we used high-throughput sequencing to assess 12 of the 13 off-target sites we had analyzed by T7EI assay (for technical reasons, we were unable to amplify the required shorter amplicon for one of the sites) as well as an additional, previously identified 5 off-target site for EMX1 site 1 in U2OS.EGFP cells (Fig. 2c) . These sequencing results showed that tru-RGNs induced mutations at substantially decreased frequencies for all 13 off-target sites relative to matched standard RGNs ( Fig. 2c and Supplementary Table 2) , with some sites showing improvements of specificity of ~5,000-fold or more ( Fig. 2d) . No indel mutations were observed with RGNs for two off-target sites (OT1-4 and OT1-11). Therefore, for these two sites, we conservatively estimated a likely upper boundary for the average indel frequencies and calculated a minimum improvement in tru-RGN specificities for these sites of >10,000-fold over standard RGNs (Fig. 2d) .
We then sought to assess whether tru-RGNs might induce additional off-target mutations in the human genome beyond those previously identified for matched full-length RGNs. Based on the results of our EGFP disruption assay, we reasoned that genomic sites with the fewest mismatches compared to the on-target site would be the most likely to be mutated. Therefore, we computationally identified sites in the human genome with one, two or three mismatches relative to tru-gRNAs targeted to VEGFA site 1, VEFGA site 3 and EMX1 site 1 ( Supplementary Table 3a ), excluding known off-target sites that had already been examined by deep sequencing ( Supplementary Table 3b ). We used the T7EI assay to examine 97 potential off-target sites, including all those with one mismatch and either all or some with two or three mismatches ( Supplementary  Tables 3c and 4) . Only one of these 97 sites showed detectable levels of indel mutations by T7EI assay in human U2OS.EGFP cells, and none showed detectable indels in human FT-HEK293 cells ( Supplementary  Table 4 ). The one site for which indels were observed was also mutated by the corresponding standard full-length RGN (Supplementary Results and Supplementary Fig. 4) , demonstrating that this offtarget site is not unique to the tru-RGN.
We also used deep sequencing to examine 30 of the most closely matched potential off-target sites (including all sites with one mismatch for all three RGNs and nearly all sites with two mismatches for the RGNs targeted to VEGFA site 1 and EMX1 site 1 ( Supplementary  Table 3d )) and found undetectable or very low rates of indel mutations ( Supplementary Table 5 ), comparable to those induced by tru-RGNs for other previously known off-target sites (Supplementary Table 2 ). Of note, the percentage of sites with mutation rates >0.1% decreases with increasing numbers of mismatches ( Supplementary  Table 3e ), validating our focus on sites with the fewest mismatches. tru-RGNs generally appear to induce either very low or undetectable levels of mutations at potential off-target sites that differ by one or two mismatches; by contrast, our previous study using standard RGNs showed high levels of mutations at numerous off-target sites bearing up to four or five mismatches 4 .
Because neither tru-gRNAs nor paired nickases completely eliminate off-target effects, we explored whether combining these strategies might further reduce such mutations. First, we used a pair of gRNAs targeted to sites in the human VEGFA gene (VEGFA site 1 and VEGFA site 4; Fig. 2e ) previously shown to work with the paired Cas9-D10A nickase approach 10 . Substitution of the full-length gRNA for VEGFA site 1 with a tru-gRNA did not adversely affect the induction of indels (Fig. 2f) or incorporation of a restriction site sequence by HDR (Fig. 2g) . We next used deep sequencing to examine mutation frequencies at four previously validated off-target sites of the VEGFA site 1 gRNA and found that mutation rates dropped below the detection limit of the sequencing assay at all four of these off-target sites when using paired nickases with one full-length gRNA and one tru-gRNA ( Supplementary Table 6 ). By contrast, both a single tru-RGN (Supplementary Table 2 ) and paired nickases with full-length gRNAs ( Supplementary Table 6 ) still induced off-target mutations at one of these four off-target sites (OT1-3). Although we substituted a tru-gRNA for only one of the two full-length gRNAs in our VEGFA paired nickase experiments, we have shown at another locus (in the EMX1 gene) that use of two tru-gRNAs with Cas9 nickase can robustly induce indels at an endogenous human gene locus ( Supplementary  Fig. 5 ). Taken together, we conclude that tru-gRNAs can further reduce the off-target effects of paired Cas9 nickases (and vice versa) without compromising the efficiency of on-target genome editing.
Our results show that tru-RGNs can, generally, introduce mutations by means of NHEJ or HDR at on-target sites with high efficiencies and show reduced mutagenic effects at closely matched off-target sites. One potential model to explain our results is that standard RGNs with full-length gRNAs might possess more affinity for their target sites than is required (perhaps not unsurprisingly because it might be beneficial for naturally occurring CRISPR systems to tolerate the introduction of alterations in the target sequence), and that truncation of the gRNA might allow the tru-RGN-DNA complex to be more sensitive to mismatches, perhaps by reducing binding energy at the gRNA-DNA interface. The concept of excess affinity affecting the specificity of DNA binding domains has previously been suggested by others for engineered zinc finger proteins 23, 24 .
The use of tru-gRNAs for improving CRISPR specificity offers important advantages over the paired Cas9 nickase strategy. tru-gRNAs should be technically simpler to implement with applications involving npg l e t t e r s multiplex [12] [13] [14] or genome-wide libraries of gRNAs 15, 16 and, unlike the paired nickase strategy, can also be used to improve the specificities of dCas9 (ref. 25) or dCas9 fusions to heterologous effector domains such as transcriptional regulatory domains [17] [18] [19] . In this regard, we note that we have found that tru-gRNAs can efficiently recruit dCas9-VP64 transcriptional activators to an endogenous human gene (Y.F., V.M.C. and J.K.J., unpublished data). The use of tru-RGNs also avoids the need for a second gRNA, which on its own might have the potential to induce additional unwanted mutations with a Cas9 nickase. For example, consistent with previously published results 7, 9, 11 , we found that a single gRNA to VEGFA site 4 was capable of efficiently inducing indel mutations with Cas9 nickase (red bar, Fig. 2f Our findings have several important implications for how to choose potential RGN target sites. The use of shorter gRNAs does not decrease the targeting range of the platform because target sites with 17 or 18 nucleotides of complementarity will each occur in random DNA with frequencies equal to those with 20 nucleotides of complementarity. Our results show that tru-gRGNs generally appear to induce very low or undetectable levels of mutagenesis at off-target sites with as few as one or two mismatches and suggest that sites with three or more mismatches will not have mutations at high frequencies, if they have any at all. Thus, a reasonable strategy to minimize off-target effects might be to choose tru-gRNA target sites that are unique in the genome and that have the smallest possible number of potential off-target sites with 1 or 2 mismatches. We have modified our web-based ZiFiT Targeter program 26, 27 so that it can identify tru-gRNA sites with 17 or 18 nucleotides of complementarity and provide the user with information about potential off-target sites that differ by 0, 1 or 2 positions in the published genomes of fruit flies, roundworm, zebrafish, mice, rats and humans using the Bowtie software 28 .
This modified version of ZiFiT Targeter is currently accessible at http://zifit.partners.org/.
Our results raise several important questions to be addressed in future experiments. Although we found that tru-gRNAs with 17 or 18 nucleotides of complementarity generally function efficiently at the intended target site and have improved specificities, it is possible that certain gRNAs with shorter and longer complementarity lengths might also possess such properties. Testing greater numbers of truncated gRNAs in future experiments should help to determine this and also whether certain characteristics, such as GC content, might predict activity levels. In addition, we assume tru-gRNAs are expressed at approximately the same levels as their full-length counterparts because they show comparable activities and because titration experiments performed for EGFP sites #1, #2 and #3 in which the amounts of gRNA and Cas9 expression vectors are varied demonstrate that shortened gRNAs give activity curves similar to their full-length counterparts (Supplementary Fig. 6 ). However, more direct, quantitative assessments of tru-gRNA expression levels will be required Table 1 . The scale of the y axis is the same for all three panels. Absolute counts of indel mutation data used to make these graphs can be found in Supplementary Table 2 . On-target sites are named as previously described 4 and as in Figure 1d . (d) Fold-improvements in off-target site activities of three tru-RGNs compared to matched standard RGNs. Values shown represent the ratio of on-target to off-target activities for tru-RGNs divided by the ratio of on-target to off-target activities of standard RGNs for the off-target sites shown, calculated using the data from c and Supplementary Table 2 . For the sites marked with an asterisk (*), no indels were observed with the tru-RGN and therefore the values shown represent conservative statistical estimates of the fold-improvements in specificities for these off-target sites (see Online Methods). npg l e t t e r s to establish this definitively and to better understand why and how tru-gRNAs function with high efficiencies and specificities. In summary, tru-gRNAs provide a simple and flexible approach to minimize the off-target effects of individual Cas9 nucleases, paired Cas9 nickases and, potentially, dCas9 fusion proteins in human cells. However, we note that definitive assessment of the relative efficacies of any platform designed to improve specificities will require the development of an unbiased approach for globally assessing off-target effects in human cells. Continued efforts to develop methods for assessing and improving specificity will further accelerate the use of Cas9-based reagents for research and therapeutic applications.
METHODS
Methods and any associated references are available in the online version of the paper.
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ONLINE METHODS
Plasmid construction. All gRNA expression plasmids were assembled by designing, synthesizing, annealing and cloning pairs of oligonucleotides (IDT) harboring the complementarity region into plasmid pMLM3636 (available from Addgene; http://www.addgene.org/crispr-cas) as previously described 4 . The resulting gRNA expression vectors encode a ~100 nt gRNA whose expression is driven by a human U6 promoter. The sequences of all oligonucleotides used to construct gRNA expression vectors are shown in Supplementary Table 7 . The Cas9 D10A nickase expression plasmid (pJDS271) bearing a mutation in the RuvC endonuclease domain was generated by mutating plasmid pJDS246 (ref. 4) using a QuikChange kit (Agilent Technologies) with the following primers: Cas9 D10A sense primer 5′-tggataaaaagtattctattggtttagccatcggcactaattccg-3′; Cas9 D10A antisense primer 5′-cggaattagtgccgatggctaaaccaatagaatactttttatcca-3′. All the targeted gRNA plasmids and the Cas9 nickase plasmids used in this study will be made available through the nonprofit plasmid distribution service Addgene.
Human cell-based EGFP disruption assay. U2OS.EGFP cells harboring a single-copy, integrated EGFP-PEST gene reporter have been previously described 22 . These cells were maintained in Advanced DMEM (Life Technologies) supplemented with 10% FBS, 2 mM GlutaMax (Life Technologies), penicillin/streptomycin and 400 µg/ml G418. To assay for disruption of EGFP expression, we transfected 2 × 10 5 U2OS.EGFP cells in duplicate with gRNA expression plasmid or an empty U6 promoter plasmid as a negative control, Cas9 expression plasmid (pJDS246) 4 and 10 ng of td-Tomato expression plasmid (to control for transfection efficiency) using a LONZA 4D-Nucleofector, with SE solution and the DN100 program according to the manufacturer's instructions. We used 25 ng/250 ng, 250 ng/750 ng, 200 ng/750 ng and 250 ng/750 ng of gRNA expression plasmid/Cas9 expression plasmid for experiments with EGFP site #1, #2, #3 and #4, respectively. Two days following transfection, cells were trypsinized and resuspended in Dulbecco's modified Eagle medium (DMEM, Invitrogen) supplemented with 10% (vol/vol) FBS (FBS) and analyzed on a BD LSRII flow cytometer. For each sample, transfections and flow cytometry measurements were performed in duplicate.
Transfection of human cells and isolation of genomic DNA.
To assess the on-target and off-target indel mutations induced by RGNs targeted to endogenous human genes, we transfected plasmids into U2OS.EGFP or FT-HEK293 (Life Technologies) cells using the following conditions: U2OS.EGFP cells were transfected using the same conditions as for the EGFP disruption assay described above. FT-HEK293 cells were transfected by seeding them at a density of 1.65 × 10 5 cells per well in 24-well plates in Advanced DMEM (Life Technologies) supplemented with 10% FBS and 2 mM GlutaMax (Life Technologies) at 37 °C in a CO 2 incubator. After 22-24 h of incubation, cells were transfected with 125 ng of gRNA expression plasmid or an empty U6 promoter plasmid (as a negative control), 375 ng of Cas9 expression plasmid (pJDS246) 4 and 10 ng of a td-Tomato expression plasmid, using Lipofectamine LTX reagent according to the manufacturer's instructions (Life Technologies). Medium was changed 16 h after transfection. For both types of cells, genomic DNA was harvested 2 d post-transfection using an Agencourt DNAdvance genomic DNA isolation kit (Beckman) according to the manufacturer's instructions. For each RGN sample to be assayed, we performed 12 individual 4D transfection replicates, isolated genomic DNA from each of these 12 transfections, and then combined these samples to create two 'duplicate' pools each consisting of six pooled genomic DNA samples. We then assessed indel mutations at on-target and off-target sites from these duplicate samples by T7EI assay, Sanger sequencing and/or deep sequencing as described below.
To assess frequencies of precise alterations introduced by HDR with ssODN donor templates, we transfected 2 × 10 5 U2OS.EGFP cells with 250 ng of gRNA expression plasmid or an empty U6 promoter plasmid (as a negative control), 750 ng Cas9 expression plasmid (pJDS246), 50 pmol of ssODN donor (or no ssODN for controls) and 10 ng of td-Tomato expression plasmid (as the transfection control). Genomic DNA was purified 3 d after transfection using Agencourt DNAdvance and assayed for the introduction of a BamHI site at the locus of interest as described below. All of these transfections were performed in duplicate.
